Morgan Stanley analyst Matthew Harrison noted that initial data from 10 patients in an investigator sponsored study of NS-065, a potential competitive exon 53 skipping drug from competitor Nippon Shinyaku, was published in Science Translational Medicine yesterday. NS-065 demonstrated some activity, but the measurement of dystrophin is not comparable to Sarepta's methods, according to the company's management, said Harrison. Nippon Shinyaku is likely to release a larger Phase 2 study with higher doses and 24 week follow-up in the coming month, he added, calling this a potential risk to watch for Sarepta, on which Harrison keeps an Equal Weight rating.